Comparison of Three Methods for the Evaluation of Cytokine Storm Risk in Early and Clinical Stage Biopharmaceutical Development

Poster   Mar 31, 2014

 
Comparison of Three Methods for the Evaluation of Cytokine Storm Risk in Early and Clinical Stage Biopharmaceutical Development
 
View Poster
 
 

Gary dos Santos and Emer Clarke

 
 

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

 
View Poster
 
 
 

OTHER POSTERS

Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets

Poster

The human immune system is comprised of a complex network of immune checkpoint receptors that are promising new immunotherapy targets for the treatment of a variety of diseases including cancer and autoimmune-mediated disorders.

READ MORE

Novel lead optimization strategy of BACE I inhibitors for the treatment of Alzheimer’s disease by Quantitative Structure-Activity Relationship (QSAR) and Physiologically-Based Pharmacokinetics (PBPK) modeling

Poster

In this study, we introduce an innovative in silico-based high throughput lead optimization strategy with QSAR and PBPK modelings using StarDrop™, ADMET predictor® and GastroPlus®.

READ MORE

Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines

Poster

Inecalcitol is a vitamin D receptor agonist currently in Phase II clinical trial in AML (acute myeloid leukemia). Inecalcitol increases the expression of CD38 at the surface of 5 multiple myeloma cell lines; therefore, inecalcitol could potentiate the clinical response of MM patients to a therapeutic anti-CD38 antibody
Inecalcitol induces the expression of the CD38 antigen at the surface of 4 AML cell lines; thus, inecalcitol could render AML patients sensitive to a therapeutic anti-CD38.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE